1	CONTROLLED SUBSTANCE AMENDMENTS	
2	2008 GENERAL SESSION	
3	STATE OF UTAH	
4	Chief Sponsor: Bradley M. Daw	
5	Senate Sponsor: Curtis S. Bramble	
6 7 8 9	Cosponsors: David Litvack Phil Riesen Greg J. Curtis Rebecca D. Lockhart Stephen E. Sandstrom John Dougall Paul Ray Stephen H. Urquhart Bradley G. Last	1
10 11	LONG TITLE	=
12	General Description:	
13	This bill amends provisions of the Utah Controlled Substances Act relating to the	
13	controlled substance database and establishes a pilot program for real-time reporting of	
15	data to, and access from, the controlled substance database. This bill also requires	
16	•	
	reporting regarding hospital admissions for drug overdoses.	
17	Highlighted Provisions:  This bill:	
18		
19	► makes admission to a hospital for drug overdose a reportable event to the	
20	Department of Health in the same manner that communicable diseases and trauma	
21	are reported;	
22	<ul> <li>specifies how the Department of Health may use the collected data;</li> </ul>	
23	<ul> <li>adds to the duties of the Department of Health's program to reduce deaths and harm</li> </ul>	1
24	from substance abuse;	
25	► defines terms;	
26	<ul> <li>provides for education of the public regarding the controlled substance database;</li> </ul>	



27	<ul> <li>makes it a third degree felony to obtain or attempt to obtain information from the</li> </ul>
28	controlled substances database for a purpose other than a purpose authorized by
29	statute or rule;
30	<ul> <li>prohibits access to, and use of, identifying information in the controlled substance</li> </ul>
31	database, by discovery, subpoena, or similar process, in certain civil, judicial,
32	administrative, or legislative proceedings;
33	<ul> <li>establishes a pilot program, beginning on July 1, 2008, and ending on July 1, 2010,</li> </ul>
34	for the real-time reporting of, and access to, controlled substance database
35	information by pharmacies, pharmaceutical facilities, and prescribing practitioners;
36	<ul> <li>grants rulemaking authority to the Division of Occupational and Professional</li> </ul>
37	Licensing in relation to the pilot program;
38	<ul> <li>requires the Division of Occupational and Professional Licensing to report on the</li> </ul>
39	pilot program and the advisability and cost of implementing the pilot program on a
40	statewide basis and the use of the controlled substance database by prescribing
41	practitioners;
42	<ul> <li>requires the Division of Occupational and Professional Licensing to implement the</li> </ul>
43	pilot program established in this bill as a permanent program on a statewide basis,
44	on or before July 1, 2010; and
45	<ul><li>makes technical changes.</li></ul>
46	Monies Appropriated in this Bill:
47	This bill appropriates:
48	► \$175,000 as an ongoing appropriation from the General Fund, for fiscal year 2008-
49	09, to the Division of Occupational and Professional Licensing; and
50	► \$650,000 from the General Fund, for fiscal year 2008-09 only, to the Division of
51	Occupational and Professional Licensing, as nonlapsing funds.
52	Other Special Clauses:
53	This bill takes effect on July 1, 2008.
54	<b>Utah Code Sections Affected:</b>
55	AMENDS:
56	<b>26-1-36</b> , as enacted by Laws of Utah 2007, Chapter 200
57	<b>26-7-1</b> , as enacted by Laws of Utah 1981, Chapter 126

<b>58-37-7.5</b> , as last amended by Laws of Utah 2007, Chapter 293
ENACTS:
26-7-4, Utah Code Annotated 1953
<b>58-37-7.8</b> , Utah Code Annotated 1953
Be it enacted by the Legislature of the state of Utah:
Section 1. Section <b>26-1-36</b> is amended to read:
26-1-36. Duty to establish program to reduce deaths and other harm from
prescription opiates used for chronic noncancer pain.
(1) As used in this section, "opiate" means any drug or other substance having an
addiction-forming or addiction-sustaining liability similar to morphine or being capable of
conversion into a drug having addiction-forming or addiction-sustaining liability.
(2) In addition to the duties listed in Section 26-1-30, the department shall develop and
implement a [two-year] three-year program in coordination with the Division of Professional
Licensing, the Utah Labor Commission, and the Utah attorney general, to:
(a) investigate the causes of and risk factors for death and nonfatal complications of
prescription opiate use and misuse in Utah for chronic pain by utilizing the Utah Controlled
Substance Database created in Section 58-37-7.5;
(b) study the risks, warning signs, and solutions to the risks associated with
prescription opiate medications for chronic pain, including risks and prevention of misuse and
diversion of those medications; [and]
(c) provide education to health care providers, patients, insurers, and the general public
on the appropriate management of chronic pain, including the effective use of medical
treatment and quality care guidelines that are scientifically based and peer reviewed[-]; and
(d) educate the public regarding:
(i) the purpose of the Controlled Substance Database established in Section 58-37-7.5;
<u>and</u>
(ii) the requirement that a person's name and prescription information be recorded on
the database when the person fills a prescription for a schedule II, III, IV, or V controlled
substance.
(3) The department shall report on the development and implementation of the

89	program required in Subsection (2) to the legislative Health and Human Services Interim
90	Committee and the legislative Business and Labor Interim Committee no later than the
91	November interim meetings in 2007 [and], 2008, and 2009. Each report shall include:
92	(a) recommendations on:
93	(i) use of the Utah Controlled Substance Database created in Section 58-37-7.5 to
94	identify and prevent:
95	(A) misuse of opiates;
96	(B) inappropriate prescribing; and
97	(C) adverse outcomes of prescription opiate medications;
98	(ii) interventions to prevent the diversion of prescription opiate medications; and
99	(iii) medical treatment and quality care guidelines that are:
100	(A) scientifically based; and
101	(B) peer reviewed; and
102	(b) (i) a measure of results against expectations under the program as of the date of the
103	report; and
104	(ii) an analysis of the application of the program, use of the appropriated funds, and the
105	impact and results of the use of the funds.
106	(4) The report provided under Subsection (3) for the 2008 and 2009 interim shall also:
107	(a) assess the effectiveness of the data collected under Section 26-7-4;
108	(b) evaluate the impact of the department and the Division of Occupational and
109	Professional Licensing efforts to educate health care providers on effective prescribing
110	practices for controlled substances; and
111	(c) provide a final cumulative analysis of the measurable effectiveness of the program
112	implemented under this section.
113	Section 2. Section <b>26-7-1</b> is amended to read:
114	26-7-1. Identification of major risk factors by department Education of public
115	Establishment of programs.
116	(1) The department shall identify the major risk factors contributing to injury, sickness,
117	death, and disability within the state and where it determines that a need exists, educate the
118	public regarding these risk factors[ <del>, and the</del> ].
119	(2) (a) The department may establish programs to reduce or eliminate [these factors

## 02-14-08 11:40 AM

# 2nd Sub. (Gray) H.B. 119

120	except that such programs shall not be] the risk factors identified under Subsection (1), unless
121	the private sector has established [if] adequate programs [exist in the private sector].
122	(b) The department shall establish a program under Section 26-7-4 and Section 26-1-36
123	for the education and prevention of substance abuse in the state.
124	Section 3. Section <b>26-7-4</b> is enacted to read:
125	26-7-4. Duty to report an individual admitted to a hospital for an overdose of a
126	controlled substance - department duties.
127	(1) Beginning October 1, 2008, a health care provider who admits an individual into a
128	hospital for an accidental or intentional drug overdose shall:
129	(a) report to the department, in accordance with Subsection (4):
130	(i) the patient's name;
131	(ii) whether the drug overdose appears to be accidental or intentional;
132	(iii) the drug found in the patient's system; and
133	(iv) the name of the prescribing practitioner if known; and
134	(b) send notice to the prescribing practitioner, if known, which informs the practitioner
135	that the prescribing practitioner's patient was admitted to the hospital for a drug overdose.
136	(2) (a) Data collected under this section shall be subject to Chapter 3, Health Statistics.
137	(b) The department shall use the data collected to:
138	(i) carry out its duties under Section 26-1-36;
139	(ii) in conjunction with the Division of Occupational and Professional Licensing, as an
140	ongoing effort:
141	(A) to develop practice guidelines for the appropriate use and prescribing of opiates
142	and controlled substances; and
143	(B) to identify practitioners who may need additional assistance or training in
144	appropriate prescribing practices for opiates and controlled substances; and
145	(iii) assess and evaluate the effectiveness of efforts to decrease the incidence of
146	substance abuse in the state.
147	(3) No person may be held civilly liable for having provided data to the department in
148	accordance with this section.
149	(4) The department shall, by administrative rule, establish:
150	(a) the data elements subject to reporting under this section:

151	(b) the medical care providers that must report under this section; and
152	(c) the time frame and format for reporting under this section.
153	Section 4. Section <b>58-37-7.5</b> is amended to read:
154	58-37-7.5. Controlled substance database Pharmacy reporting requirements
155	Access Penalties.
156	(1) As used in this section:
157	(a) "Board" means the Utah State Board of Pharmacy created in Section 58-17b-201.
158	[(a)] (b) "Database" means the controlled substance database created in this section.
159	[(b)] (c) "Database manager" means the person responsible for operating the database,
160	or [his] the person's designee.
161	[(c)] (d) "Division" means the Division of Occupational and Professional Licensing
162	created in Section 58-1-103.
163	[(d)] (e) "Health care facility" [has the same definition as] is as defined in Section
164	26-21-2.
165	[(e)] (f) "Pharmacy" or "pharmaceutical facility" [has the same definition as] is as
166	defined in Section 58-17b-102.
167	(2) (a) There is created within the division a controlled substance database.
168	(b) The division shall administer and direct the functioning of the database in
169	accordance with this section. The division may under state procurement laws contract with
170	another state agency or private entity to establish, operate, or maintain the database. The
171	division in collaboration with the board shall determine whether to operate the database within
172	the division or contract with another entity to operate the database, based on an analysis of
173	costs and benefits.
174	(c) The purpose of the database is to contain data as described in this section regarding
175	every prescription for a controlled substance dispensed in the state to any person other than an
176	inpatient in a licensed health care facility.
177	(d) Data required by this section shall be submitted in compliance with this section to
178	the manager of the database by the pharmacist in charge of the drug outlet where the controlled
179	substance is dispensed.
180	(3) The [Utah State Board of Pharmacy created in Section 58-17b-201] board shall
181	advise the division regarding:

182	(a) establishing, maintaining, and operating the database;
183	(b) access to the database and how access is obtained; and
184	(c) control of information contained in the database.
185	(4) The pharmacist in charge shall, regarding each controlled substance dispensed by a
186	pharmacist under [his] the pharmacist's supervision other than those dispensed for an inpatient
187	at a health care facility, submit to the manager of the database the following information, by a
188	procedure and in a format established by the division:
189	(a) name of the prescribing practitioner;
190	(b) date of the prescription;
191	(c) date the prescription was filled;
192	(d) name of the person for whom the prescription was written;
193	(e) positive identification of the person receiving the prescription, including the type of
194	identification and any identifying numbers on the identification;
195	(f) name of the controlled substance;
196	(g) quantity of controlled substance prescribed;
197	(h) strength of controlled substance;
198	(i) quantity of controlled substance dispensed;
199	(j) dosage quantity and frequency as prescribed;
200	(k) name of drug outlet dispensing the controlled substance;
201	(l) name of pharmacist dispensing the controlled substance; and
202	(m) other relevant information as required by division rule.
203	(5) The division shall maintain the database in an electronic file or by other means
204	established by the division to facilitate use of the database for identification of:
205	(a) prescribing practices and patterns of prescribing and dispensing controlled
206	substances;
207	(b) practitioners prescribing controlled substances in an unprofessional or unlawful
208	manner;
209	(c) individuals receiving prescriptions for controlled substances from licensed
210	practitioners, and who subsequently obtain dispensed controlled substances from a drug outlet
211	in quantities or with a frequency inconsistent with generally recognized standards of dosage for
212	that controlled substance; and

243

213	(d) individuals presenting forged or otherwise false or altered prescriptions for
214	controlled substances to a pharmacy.
215	(6) (a) The division shall by rule establish the electronic format in which the
216	information required under this section shall be submitted to the administrator of the database.
217	(b) The division shall ensure the database system records and maintains for reference:
218	(i) identification of each person who requests or receives information from the
219	database;
220	(ii) the information provided to each person; and
221	(iii) the date and time the information is requested or provided.
222	(7) The division shall make rules to:
223	(a) effectively enforce the limitations on access to the database as described in
224	Subsection (8); and
225	(b) establish standards and procedures to ensure accurate identification of individuals
226	requesting information or receiving information without request from the database.
227	(8) The manager of the database shall make information in the database available only
228	to the following persons, and in accordance with the limitations stated and division rules:
229	(a) personnel of the division specifically assigned to conduct investigations related to
230	controlled substances laws under the jurisdiction of the division;
231	(b) authorized division personnel engaged in analysis of controlled substance
232	prescription information as a part of the assigned duties and responsibilities of their
233	employment;
234	(c) employees of the Department of Health whom the director of the Department of
235	Health assigns to conduct scientific studies regarding the use or abuse of controlled substances,
236	provided that the identity of the individuals and pharmacies in the database are confidential and
237	are not disclosed in any manner to any individual who is not directly involved in the scientific
238	studies;
239	(d) a licensed practitioner having authority to prescribe controlled substances, to the
240	extent:
241	(i) the information relates specifically to a current patient of the practitioner, to whom
242	the practitioner is prescribing or considering prescribing any controlled substance;

(ii) the information relates specifically to an individual who has access to the

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

- practitioner's Drug Enforcement Administration number, and the practitioner suspects that the individual may have used the practitioner's Drug Enforcement Administration identification number to fraudulently acquire or prescribe controlled substances; or
- (iii) the information relates to the practitioner's own prescribing practices, except when specifically prohibited by the division by administrative rule;
- (e) a licensed pharmacist having authority to dispense controlled substances to the extent the information relates specifically to a current patient to whom that pharmacist is dispensing or considering dispensing any controlled substance;
- (f) federal, state, and local law enforcement authorities, and state and local prosecutors, engaged as a specified duty of their employment in enforcing laws:
  - (i) regulating controlled substances; or
  - (ii) investigating insurance fraud, Medicaid fraud, or Medicare fraud; and
- (g) an individual who is the recipient of a controlled substance prescription entered into the database, upon providing evidence satisfactory to the database manager that the individual requesting the information is in fact the person about whom the data entry was made.
- (9) Any person who knowingly and intentionally releases any information in the database in violation of the limitations under Subsection (8) is guilty of a third degree felony.
- (10) (a) Any person who obtains or attempts to obtain information from the database by misrepresentation or fraud is guilty of a third degree felony.
- (b) Any person who obtains or attempts to obtain information from the database for a purpose other than a purpose authorized by this section or by rule is guilty of a third degree felony.
- (11) (a) A person may not knowingly and intentionally use, release, publish, or otherwise make available to any other person or entity any information obtained from the database for any purpose other than those specified in Subsection (8). Each separate violation of this Subsection (11) is a third degree felony and is also subject to a civil penalty not to exceed \$5,000.
- (b) The procedure for determining a civil violation of this Subsection (11) shall be in accordance with Section 58-1-108, regarding adjudicative proceedings within the division.
- (c) Civil penalties assessed under this Subsection (11) shall be deposited in the General Fund as a dedicated credit to be used by the division under Subsection 58-37-7.7(1).

275	(12) (a) The failure of a pharmacist in charge to submit information to the database as
276	required under this section after the division has submitted a specific written request for the
277	information or when the division determines the individual has a demonstrable pattern of
278	failing to submit the information as required is grounds for the division to take the following
279	actions in accordance with Section 58-1-401:
280	(i) refuse to issue a license to the individual;
281	(ii) refuse to renew the individual's license;
282	(iii) revoke, suspend, restrict, or place on probation the license;
283	(iv) issue a public or private reprimand to the individual;
284	(v) issue a cease and desist order; and
285	(vi) impose a civil penalty of not more than \$1,000 for each dispensed prescription
286	regarding which the required information is not submitted.
287	(b) Civil penalties assessed under Subsection (12)(a)(vi) shall be deposited in the
288	General Fund as a dedicated credit to be used by the division under Subsection 58-37-7.7(1).
289	(c) The procedure for determining a civil violation of this Subsection (12) shall be in
290	accordance with Section 58-1-108, regarding adjudicative proceedings within the division.
291	(13) An individual who has submitted information to the database in accordance with
292	this section may not be held civilly liable for having submitted the information.
293	(14) All department and the division costs necessary to establish and operate the
294	database shall be funded by appropriations from:
295	(a) the Commerce Service Fund; and
296	(b) the General Fund.
297	(15) All costs associated with recording and submitting data as required in this section
298	shall be assumed by the submitting pharmacy.
299	(16) (a) Except as provided in Subsection (16)(b), data provided to, maintained in, or
300	accessed from the database that may be identified to, or with, a particular person is not subject
301	to discovery, subpoena, or similar compulsory process in any civil, judicial, administrative, or
302	legislative proceeding, nor shall any individual or organization with lawful access to the data
303	be compelled to testify with regard to the data.
304	(b) The restrictions in Subsection (16)(a) do not apply to:
305	(i) a criminal proceeding; or

306	(ii) a civil, judicial, or administrative action brought to enforce the provisions of this
307	section, Section 58-37-7.7, or Section 58-37-7.8.
308	Section 5. Section <b>58-37-7.8</b> is enacted to read:
309	58-37-7.8. Pilot program for real-time reporting for controlled substance database
310	Statewide implementation.
311	(1) (a) As used in this section:
312	(i) "Pilot area" means the areas of the state that the division determines to operate the
313	pilot program in, under Subsection (3), which may include:
314	(A) the entire state; or
315	(B) geographical areas within the state.
316	(ii) "Pilot program" means the pilot program described in this section.
317	(b) The definitions in Subsection 58-37-7.5(1) apply to this section.
318	(2) There is established a pilot program for real-time reporting of data to, and access to
319	data from, the database by a pharmacy, a pharmaceutical facility, or a prescribing practitioner
320	beginning on July 1, 2008, and ending on July 1, 2010.
321	(3) In addition to fulfilling the requirements of Sections 58-37-7.5 and 58-37-7.7 on a
322	statewide basis, the division shall, in accordance with Subsection (4), upgrade, administer, and
323	direct the functioning of the database in geographical areas specified by the division, or on a
324	statewide basis, in a manner that provides for real-time reporting of information entered into,
325	and accessed from, the database by a pharmacy or pharmaceutical facility.
326	(4) The division shall, under state procurement laws, and with the technical assistance
327	of the Department of Technology Services, contract with a private entity to upgrade, operate,
328	and maintain the database in the pilot area.
329	(5) (a) All provisions and requirements of the statewide database, described in Sections
330	58-37-7.5 and 58-37-7.7, are applicable to the database in the pilot area, to the extent that they
331	do not conflict with the requirements of this section.
332	(b) For purposes of Section 58-37-7.5, Section 58-37-7.7, and this section, the database
333	in the pilot area is considered part of the statewide database.
334	(6) A pharmacy or pharmaceutical facility shall cooperate with the division, or the
335	division's designee, to provide real-time submission of, and access to, information for the
336	database:

331	(a) in the pilot area; and
338	(b) when the division implements the pilot program as a permanent program under
339	Subsection (10), on a statewide basis.
340	(7) The penalties and enforcement provisions described in Sections 58-37-7.5 and
341	58-37-7.7 apply to enforce the provisions of this section in relation to a pharmacy or
342	pharmaceutical facility that is located in, or operates in, the pilot area.
343	(8) The division may make rules, in accordance with Title 63, Chapter 46a, Utah
344	Administrative Rulemaking Act, to provide for the real-time reporting of, and access to,
345	information in accordance with the requirements of this section.
346	(9) During the Legislature's 2009 interim, the division shall report to the Health and
347	Human Services Interim Committee regarding:
348	(a) the implementation, operation, and impact of the pilot program established in this
349	section;
350	(b) the progress made by the division in implementing the pilot program on a statewide
351	basis;
352	(c) the advisability of, and projected costs of, implementing the pilot program on a
353	statewide basis; and
354	(d) the use of the database by prescribing practitioners.
355	(10) The division shall, on or before July 1, 2010, implement the pilot program as a
356	permanent program on a statewide basis.
357	(11) (a) The division shall, through the private entity contracted with under Subsection
358	(4), provide, free of charge, to a pharmacy or pharmaceutical facility that is required to comply
359	with Subsection (6), software, software installation assistance, and training, that will enable the
360	pharmacy or pharmaceutical facility to comply with Subsection (6).
361	(b) Notwithstanding Subsection (11)(a), a pharmacy or pharmaceutical facility required
362	to comply with Subsection (6) may, instead of accepting installation of the software provided
363	by the division under Subsection (11)(a), modify its own software in order to comply with the
364	requirements of Subsection (6), if the modification is made:
365	(i) except as provided in Subsection (11)(d), at the expense of the pharmacy or
366	pharmaceutical facility;
367	(ii) in consultation with the division; and

368	(iii) within six months after the division notifies the pharmacy or pharmaceutical
369	facility, in writing, of the division's intention to install the software described in Subsection
370	(11)(a).
371	(c) The division shall, through the private entity contracted with under Subsection (4),
372	cooperate with a pharmacy or pharmaceutical facility that is required to comply with
373	Subsection (6), to ensure that the installation and operation of the software described in
374	Subsection (11)(a), or the provision of information from the pharmacy or pharmaceutical
375	facility to the database:
376	(i) complies with the security standards described in 45 CFR Parts 160, 162, and 164,
377	Health Insurance Reform: Security Standards;
378	(ii) does not interfere with the proper functioning of the pharmacy's or pharmaceutical
379	facility's software or computer system; and
380	(iii) in order to minimize changes in existing protocols, provides, to the extent
381	practicable, for the transmission of data in the same manner that pharmacies currently transmit
382	information to insurance companies.
383	(d) The division may, within funds appropriated by the Legislature for this purpose,
384	reimburse a pharmacy for all or part of the costs of the in-house programing described in
385	Subsection (11)(b), if:
386	(i) the pharmacy requests the reimbursement, in writing:
387	(ii) the pharmacy provides proof of the costs for the in-house programming to the
388	division;
389	(iii) the pharmacy requests the reimbursement prior to a deadline established by the
390	division; and
391	(iv) except as provided in Subsection (11)(e), the division pays an equal reimbursement
392	amount to each pharmacy that complies with Subsections (11)(d)(i) through (iii).
393	(e) The division may reimburse a pharmacy described in Subsection (11)(d)(iv) for an
394	amount that is less than the reimbursement paid to other pharmacies described in Subsection
395	(11)(d)(iv), if:
396	(i) the proof of costs for in-house programming provided by the pharmacy establishes a
397	cost less than the amount reimbursed to the other pharmacies; and
398	(ii) the amount reimbursed to the pharmacy is equal to the amount established by the

399	proof of costs for in-house programming submitted by the pharmacy.
400	Section 6. Appropriation.
401	(1) There is appropriated:
402	(a) as an ongoing appropriation, subject to future budget constraints, \$175,000 from the
403	General Fund for the fiscal year 2008-09, to the Division of Occupational and Professional
404	Licensing to maintain and operate the controlled substance database; and
405	(b) \$650,000 from the General Fund, for the fiscal year 2008-09 only, to the Division
406	of Occupational and Professional Licensing to:
407	(i) implement and operate the pilot program described in this bill; and
408	(ii) if any of the funds described in this Subsection (1)(b) are available after paying the
409	costs to implement and operate the pilot program under Subsection (1)(b)(i), reimburse a
410	pharmacy for the costs of in-house programming, in accordance with Subsection
411	58-37-7.8(11)(d).
412	(2) The \$650,000 appropriated from the General Fund, under Subsection (2), shall be
413	nonlapsing.
414	Section 7. Effective date.
415	This bill takes effect on July 1, 2008.